GlassScriptPhysician profile
L Stehen Buchanan
NPI 1891959060
$1,231,188.73
in general payments reported to CMS, 2019-2025
7 companies · $7,008 in 2025
The $7,008 reported for 2025 was more than what 97% of Endodontics providers received nationally (typical 2025 total: $58.83).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $19K · 2021: $18K · 2022: $345K · 2023: $475K · 2024: $343K · 2025: $7,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $825K · Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $824,745.10 |
| Food and Beverage | $195.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerr Corporation | $797,862.50 | 2021-2023 | Zenflex, Elements E-Motion, Elements Free |
| Envista Holdings Corporation | $334,697.85 | 2024 | Elements E-Motion, Zenflex, Elements Free |
| Tulsa Dental Products LLC | $97,972.22 | 2019-2025 | Gt Series X Obturator |
| Biolase, INC. | $347.86 | 2021 | |
| Sonendo INC | $277.39 | 2019-2025 | Gentlewave G4 Console |
| Dentsply Sirona INC | $30.91 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$164,873.17 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw L Stehen Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.